Besides, our analysis revealed that this different rate of prescription of some co-medications, especially antibacterials for systemic use, agents acting on the renin–angiotensin system, and beta-blockers, between DAA-treated and untreated HCV+ patients disappeared in those who also had T2D. The gene discussed is REN; the disease is type 2 diabetes mellitus.